title: Reply to Comments From Dr Lozano, et al--Concerning the Prevalence of Lithium-Associated Hyperparathyroidism.
authors.affiliation: Department of Geriatrics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.Psychiatric Research Centre, Örebro University, Örebro, Sweden.Department of Psychiatry, Ryhov Hospital, Jönköping, Sweden.Department of Surgery, Ryhov Hospital, Jönköping, Sweden.Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
authors.forename: Adrian David
authors.initials: AD
authors.lastname: Meehan
authors.forename: Mats B
authors.initials: MB
authors.lastname: Humble
authors.forename: Payam
authors.initials: P
authors.lastname: Yazarloo
authors.forename: Johannes
authors.initials: J
authors.lastname: Järhult
authors.forename: Göran
authors.initials: G
authors.lastname: Wallin
mesh_terms: D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000139:chemically induced*; D018020:Lithium Compounds / Q000009:adverse effects*; D008297:Male
chemical_list: D018020:Lithium Compounds